Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

CTMX CytomX Therapeutics Inc

1,59

-0,01 (-0,63%)

27 Apr 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024

Click Here for more CytomX Therapeutics Charts.

CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024

Click Here for more CytomX Therapeutics Charts.

News CytomX Therapeutics Inc

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Montag 8 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Mittwoch 3 April 2024 (4 Wochen vor) • GlobeNewswire Inc.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Donnerstag 21 März 2024 (1 Monat vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Montag 18 März 2024 (1 Monat vor) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Montag 11 März 2024 (2 Monate vor) • Edgar (US Regulatory)

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
Montag 11 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 11 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Montag 11 März 2024 (2 Monate vor) • Edgar (US Regulatory)

U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher
Montag 11 März 2024 (2 Monate vor) • IH Market News

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Montag 4 März 2024 (2 Monate vor) • GlobeNewswire Inc.

CytomX Therapeutics to Present at Upcoming March Investor Conferences
Dienstag 27 Februar 2024 (2 Monate vor) • GlobeNewswire Inc.

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
Mittwoch 24 Januar 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere CytomX Therapeutics Inc News-Artikel

Health Care Select Sector

Invesco QQQ Trust Series 1

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen